FDA and EMA approve multiple new treatments for breast cancer, pulmonary fibrosis, and rare disorders while research highlights emerging health risks from sugar substitutes and obesity-related asthma complications.

The FDA approved datopotamab deruxtecan, an antibody drug conjugate, for certain patients with triple-negative breast cancer, marking a significant therapeutic advance for this aggressive cancer subtype with limited treatment options.

The EMA granted conditional authorization for the first drug treating severe PIK3CA-related overgrowth disorders in children aged 2 and older and adults, addressing a previously untreated life-threatening rare genetic condition.

The EMA approved a new oral therapy for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, expanding limited treatment options for these debilitating fibrotic lung diseases.

The EMA backed camizestrant, a selective estrogen receptor degrader, for breast cancer treatment after phase 3 data showed improved progression-free survival when combined with CDK4/6 inhibitors, despite FDA's earlier decision not to approve.

CRISPR-Cas9 gene editing treatments are demonstrating potential as 'one-time' cardiovascular disease therapies with lasting effects, though long-term safety monitoring will require years of additional research and surveillance.

A Brazilian cohort study found that maternal chikungunya infection increases infant hospitalization risk through age 3, with findings informing global surveillance strategies and vaccination policy development.

Emerging research suggests sugar substitute sweeteners may negatively impact metabolism, gut microbiome composition, and cardiovascular health more significantly than previously believed, challenging their safety profile as alternatives to sugar.

New evidence indicates that obesity-related asthma severity may be driven by elevated leptin levels, gut dysbiosis, and altered innate immune responses rather than simple weight factors alone, suggesting novel therapeutic targets.